Trial Profile
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation (CTOT-11)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Acronyms CTOT-11
- 09 Jul 2019 Results published in the Journal of the American College of Cardiology
- 14 Apr 2018 Results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 21 Nov 2012 Actual initiation date changed from Feb 2011 to Sep 2011 as reported by ClinicalTrials.gov.